|Date:||Monday, March 21, 2016|
|Time:||8:30 am Eastern time|
|Dial-in numbers:||(855) 539-0895 (U.S. and Canada) or (412) 455-6027|
|Live webcast:||www.bellerophon.com, under “Investor Relations”|
The teleconference replay will be available three hours after the completion through
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). The Company’s plans also call for the completion of further work on the use of INOpulse to treat PH-COPD and PH-IPF during 2016. For more information, please visit www.bellerophon.com.
Contact At Bellerophon:
Fabian Tenenbaum, Chief Financial Officer (908) 574-4767 At Rx Communications Group: Melody Carey(917) 322-2571